Status:
COMPLETED
An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Male Volunteers
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
Study of what the body does to drug BMS-986165 when it is taken together with pyrimethamine
Eligibility Criteria
Inclusion
- Patients must be willing and able to complete all study-specific procedures and visits
- Healthy patients, as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram, and clinical laboratory determinations
- Body mass index (BMI) of 18 to 32 kg/m2, inclusive, at screening
- Normal renal function at screening
Exclusion
- Any medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of or active liver disease
- Current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug
- History or presence of clinically significant acute or chronic bacterial, fungal, or viral infection (eg, pneumonia, septicemia) within the 3 months prior to screening
- Additional criteria may apply
Key Trial Info
Start Date :
September 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 29 2019
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT04086719
Start Date
September 12 2019
End Date
October 29 2019
Last Update
August 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PRA Health Sciences - Salt Lake
Salt Lake City, Utah, United States, 84124